RAPT Therapeutics, Inc. (RAPT) Liabilities and Shareholders Equity (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $108.5 million as the latest value for Q3 2024.
- Quarterly Liabilities and Shareholders Equity fell 45.69% to $108.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $391.5 million through Dec 2024, down 53.52% year-over-year, with the annual reading at $173.3 million for FY2023, 34.89% down from the prior year.
- Liabilities and Shareholders Equity hit $108.5 million in Q3 2024 for RAPT Therapeutics, down from $127.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $266.2 million in Q4 2022 to a low of $105.9 million in Q1 2021.
- Historically, Liabilities and Shareholders Equity has averaged $179.5 million across 5 years, with a median of $187.5 million in 2022.
- Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 77.06% in 2022 and later crashed 45.69% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $119.0 million in 2020, then surged by 66.96% to $198.6 million in 2021, then skyrocketed by 34.02% to $266.2 million in 2022, then tumbled by 34.89% to $173.3 million in 2023, then crashed by 37.42% to $108.5 million in 2024.
- Business Quant data shows Liabilities and Shareholders Equity for RAPT at $108.5 million in Q3 2024, $127.2 million in Q2 2024, and $155.8 million in Q1 2024.